Equities analysts expect that TESARO, Inc. (NASDAQ:TSRO) will report sales of $118.02 million for the current fiscal quarter, according to Zacks. Seven analysts have made estimates for TESARO’s earnings. The lowest sales estimate is $33.60 million and the highest is $162.60 million. TESARO posted sales of $3.73 million during the same quarter last year, which suggests a positive year over year growth rate of 3,064.1%. The company is scheduled to report its next earnings report on Thursday, November 2nd.

On average, analysts expect that TESARO will report full-year sales of $118.02 million for the current year, with estimates ranging from $108.10 million to $280.80 million. For the next year, analysts anticipate that the business will report sales of $484.25 million per share, with estimates ranging from $312.94 million to $636.60 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that cover TESARO.

TESARO (NASDAQ:TSRO) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share for the quarter, missing the consensus estimate of ($2.52) by ($0.30). TESARO had a negative net margin of 1,301.19% and a negative return on equity of 104.00%. The firm had revenue of $29.50 million during the quarter, compared to the consensus estimate of $18.61 million. During the same period in the prior year, the business posted ($1.28) earnings per share. TESARO’s quarterly revenue was down 17.6% compared to the same quarter last year.

A number of research firms have recently issued reports on TSRO. Oppenheimer Holdings, Inc. began coverage on shares of TESARO in a report on Thursday, May 25th. They issued an “outperform” rating and a $183.00 price objective on the stock. Cann reiterated an “outperform” rating on shares of TESARO in a report on Wednesday, May 24th. Credit Suisse Group set a $198.00 price objective on shares of TESARO and gave the company a “buy” rating in a report on Monday, June 5th. Wedbush upgraded shares of TESARO to an “outperform” rating and set a $168.00 price objective on the stock in a report on Monday, June 5th. Finally, FBR & Co lowered their price objective on shares of TESARO from $200.00 to $195.00 and set a “mkt perform” rating on the stock in a report on Monday, June 5th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. TESARO presently has a consensus rating of “Buy” and an average price target of $171.42.

In other TESARO news, VP Grant C. Bogle sold 14,167 shares of TESARO stock in a transaction on Friday, September 1st. The shares were sold at an average price of $135.00, for a total transaction of $1,912,545.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Edward C. English sold 10,862 shares of TESARO stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $134.92, for a total transaction of $1,465,501.04. Following the transaction, the vice president now directly owns 6,258 shares of the company’s stock, valued at $844,329.36. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 25,100 shares of company stock valued at $3,387,465. Company insiders own 40.50% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in TSRO. BlackRock Inc. boosted its position in TESARO by 4,504.8% during the first quarter. BlackRock Inc. now owns 3,409,657 shares of the biopharmaceutical company’s stock worth $524,643,000 after purchasing an additional 3,335,611 shares during the period. Janus Henderson Group PLC bought a new position in TESARO during the second quarter worth $100,301,000. PointState Capital LP bought a new position in TESARO during the second quarter worth $85,971,000. TIAA CREF Investment Management LLC boosted its position in TESARO by 167.9% during the first quarter. TIAA CREF Investment Management LLC now owns 367,519 shares of the biopharmaceutical company’s stock worth $56,550,000 after purchasing an additional 230,353 shares during the period. Finally, Pioneer Investment Management Inc. boosted its position in TESARO by 195.6% during the second quarter. Pioneer Investment Management Inc. now owns 317,753 shares of the biopharmaceutical company’s stock worth $44,441,000 after purchasing an additional 210,273 shares during the period.

TESARO (TSRO) traded up 0.08% during trading on Friday, reaching $115.33. 191,162 shares of the company’s stock were exchanged. TESARO has a 12 month low of $96.52 and a 12 month high of $192.94. The firm’s market cap is $6.25 billion. The firm’s 50-day moving average price is $122.01 and its 200-day moving average price is $140.92.

WARNING: “$118.02 Million in Sales Expected for TESARO, Inc. (TSRO) This Quarter” was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was stolen and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/09/15/118-02-million-in-sales-expected-for-tesaro-inc-tsro-this-quarter.html.

About TESARO

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Get a free copy of the Zacks research report on TESARO (TSRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.